Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OtherDepreciationAndAmortization.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net income (loss) | $(10,831) | $41,256 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation and amortization | 748 | 822 |
| Amortization and accretion on investment securities, net | (1,539) | (749) |
| Future royalty payment contingency interest accretion | — | 1,306 |
| Share-based compensation | 10,494 | 9,420 |
| Loss on disposal of property and equipment | — | 35 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's D&A?
- Theravance Biopharma (TBPH) reported D&A of $367K in Q2 2026.
- How has Theravance Biopharma's D&A changed year-over-year?
- Theravance Biopharma's D&A decreased by 10.3% year-over-year, from $409K to $367K.
- What is the long-term trend for Theravance Biopharma's D&A?
- Over 4 years (2021 to 2025), Theravance Biopharma's D&A has grown at a -23.7% compound annual growth rate (CAGR), from $4.8M to $1.63M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Theravance Biopharma's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude